Filling a syringe

CP018 Risperidone Depot

CP018 is a long-acting injection of risperidone that uses Critical Pharmaceuticals’ proprietary CriticalMix™ drug delivery technology. It is being developed as a once every two week injection.

Risperidone is the most widely prescribed medication in its class for the treatment of schizophrenia and other psychiatric disorders and is the only drug approved by the FDA for the treatment of schizophrenia in adolescents. Risperidone is effective against both the positive and negative symptoms of schizophrenia and produces fewer side effects than conventional antipsychotic drugs. Schizophrenia effects more than 24 million people worldwide and global sales for risperidone is currently estimated to be $4.2 billion annually.

Several oral atypical antipsychotics are available for the management of schizophrenia but their benefits are limited by non-compliance. Long-acting injectable risperidone makes an important contribution to the management of schizophrenia by ensuring greater patient compliance and CP018 is an attractive alternative to current therapies.

CriticalMix Technology

CriticalMix rig

CriticalMix enables the manufacture of highly active sustained release depot products for bimonthly, monthly or less frequent injection.

Read more

CP024 Nasal GH

measuring height

CP024 has completed two Phase 1 clinical trials where our intranasal growth hormone has shown comparable activity to injection.

Read more

Dr Andy Lewis, Critical Pharmaceuticals
“Our competitors can make sustained release formulations of small molecular weight drugs, but they need to use a lot of solvents to do it. We realised that using solvents when making medicines to be given to patients creates a lot of problems for the manufacturers. Firstly, many of these solvents are very toxic, and without costly extraction procedures, residues can be left in the products. Proving to the regulators that these extraction procedures are effective is also costly and time consuming, so when you want to get your product to market as quickly as possible you would rather not have to do it. Secondly, disposing of large amounts of these solvents is also very expensive and carries with it environmental concerns. By using our CriticalMix™ technology we can formulate drugs in a dry state without using any solvents at all.”